CDK19 and cancer: Certain MEDs were found to be both over- and underexpressed in the same cancer entity [e.g. MED28 in bladder cancer (both 26%, n = 28/109); CDK19 in kidney cancer (overexpression 66%, n = 33/50; underexpression 32%, n = 16/50)].